Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Dec 2016 09:28

RNS Number : 0712S
Proteome Sciences PLC
16 December 2016
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

PROTEOME SCIENCES PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

VULPES LIFE SCIENCES FUND

 

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

14 DECEMBER 2016

6. Date on which issuer notified:

15 DECEMBER 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0003104196

36,573,125

36,573,125

52,973,125

52,973,125

18.00%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

52,973,125

18.00%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

executive.pa@proteomics.com 

 

14. Contact name:

Victoria Birse

15. Contact telephone number:

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

VULPES LIFE SCIENCES FUND

Contact address

(registered office for legal entities)

 

c/o Maples Corporate Services Limited, PO

Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Stephen Diggle

Contact address

 

One George Street #07-03 Singapore 049145

 

Phone number & email

 

Tel: (65) 6538 1998 (Main)

Email: sdiggle@vulpesinvest.com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

Director

C: Additional information

Email address: Complete the required TR-1 form and email it to: Major shareholdings majorshareholdings@fca.gov.uk Fax number: You can print the TR-1 form, complete it and fax it to: 020 7066 0050

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGAPPUPQUBQ
Date   Source Headline
2nd Jul 20083:42 pmPRNNotifiable Interest
27th Jun 20089:50 amPRNAnnual Report and Accounts
24th Jun 20087:05 amPRNLoan Agreement
24th Jun 20087:00 amPRNFinal Results
12th Jun 20087:00 amPRNNotice of Allowance for US Patent
20th May 20082:43 pmPRNHolding(s) in Company
8th May 20087:00 amPRNSENS-IT-IV Framework 6 EU Grant Award
25th Apr 20082:30 pmPRNBlocklisting - Interim Review
17th Apr 200810:28 amPRNTotal Voting Rights
1st Apr 20083:20 pmPRNHolding(s) in Company
20th Mar 200812:22 pmPRNTMT Patent Update
13th Mar 20082:55 pmPRNHolding(s) in Company
13th Mar 20082:52 pmPRNHolding(s) in Company
20th Feb 20082:26 pmPRNHolding(s) in Company
18th Feb 200812:25 pmPRNHolding(s) in Company
14th Feb 20085:45 pmPRNHolding(s) in Company
13th Feb 20083:04 pmPRNHolding(s) in Company
5th Feb 20088:36 amPRNStatement re Share Price Movement
23rd Jan 20084:21 pmPRNHolding(s) in Company
18th Jan 20083:53 pmPRNHolding(s) in Company
21st Dec 20077:00 amPRNCurrent Trading
20th Nov 20075:24 pmPRNNotifiable Interests
20th Nov 20075:01 pmPRNNotifiable Interest
19th Nov 20074:33 pmPRNNotifiable Interest (TR-1)
13th Nov 20075:38 pmPRNStatement re Issuance of US Patent
5th Nov 20073:57 pmPRNNotifiable Interest
31st Oct 20077:00 amPRNBlocklisting - Interim Review
10th Oct 20073:31 pmPRNNotifiable Interest
8th Oct 20072:34 pmPRNStatement regarding mailing of interim report
2nd Oct 20074:28 pmPRNDirectorate Change
28th Sep 20078:00 amPRNInterim Results
21st Sep 20079:54 amPRNPress Release re Intronn Inc.
6th Sep 20074:27 pmPRNNotifiable Interest
17th Aug 20076:15 pmPRNAIM Rule 26 & Adviser Name
30th Jul 20077:00 amPRNStatement re US Patent Allowed
25th Jul 200712:03 pmPRNDirector's Dealing
12th Jul 20072:58 pmPRNNotifiable Interest
2nd Jul 20074:59 pmPRNDirector/PDMR Shareholding
29th Jun 20078:15 amPRNFurther Loan Agreement
29th Jun 20078:00 amPRNFinal Results
22nd May 20073:50 pmPRNNotifiable Interest
15th May 200711:38 amPRNGrant of European Patent
14th May 200711:40 amPRNNotifiable Interest
10th May 20075:03 pmPRNNotifiable Interest
8th May 20078:30 amPRNNotice of Allowance of TMT1 Patent in Canada
25th Apr 20073:32 pmPRNBlocklisting - Interim Review
20th Apr 200711:03 amPRNDirector's Dealings
19th Apr 20072:26 pmPRNNotifiable Interest
18th Apr 20078:30 amPRNService Agreement with Onconome Inc.
13th Apr 200712:20 pmPRNNotifiable Interest

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.